Positive impactResults

Balaji Amines Q2 Results: Net profit jumps nearly 2-fold on 37% revenue growth

CNBC-TV18 1 hr ago·2 Nov 2026, 5:04 pm

Balaji Amines has reported a strong set of numbers for the second quarter, with its net profit nearly doubling year-on-year to ₹67.3 crore. This growth was driven by a 37% rise in revenue to ₹468 crore, alongside a significant expansion in earnings before interest, taxes, depreciation, and amortization (EBITDA). The company's operating margins have also improved, rising to 21.7% from 17.6% in the same period last year.

For investors, the results indicate that the company is gaining scale and operating more efficiently. The jump in margins suggests that the company is managing its costs well despite a broader increase in sales. The stock will likely be watched closely to see if this momentum continues in the upcoming quarters and how the company plans to utilize its improved profitability.

Excerpt from CNBC-TV18

Published On Nov 2, 2026 | 22:29 IST Last Updated On Nov 2, 2026 | 22:34 IST Strong demand propelled the specialty chemical maker's earnings significantly higher, driven by robust top-line expansion and wider operating margins across core product segments. Discover how raw material price trends could impact upcoming…
Read the original at CNBC-TV18

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Balaji Amines (BALAMINES).
  • Category: Results.
  • AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for Balaji Amines. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC-TV18.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.